Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$APVS Breaking 44's resistance point would be pretty big... pic.twitter.com/V7GzwQnbWO
— Heizenberger (@HeizenbergerOTC) March 7, 2019
$APVS Big bids coming in... people might be catching on pic.twitter.com/EsbCS8f8qA
— Heizenberger (@HeizenbergerOTC) March 5, 2019
$APVS Lots of penant breaks causing runs happening today. APVS chart has similar setup on 30 Min. im just waiting for the break to happen here too and the volume to come surging in. pic.twitter.com/7OsogSbBT0
— Heizenberger (@HeizenbergerOTC) March 5, 2019
As soon as this low vol manipulation is done we’ll be right back up.
$APVS I dont know who is giving away the cheap shares in the 3s but thats the loading zone... not the area you sell for a loss... pic.twitter.com/0hKep4ElsY
— Heizenberger (@HeizenbergerOTC) March 5, 2019
$APVS Sellers seem to be out at this point, 10 min shows a new base is forming and allowing cheap entry for next leg. Only a matter of time before this takes off. Very little volume today but when it comes this thing moves on air with 30 M float. Still holding. pic.twitter.com/IavFQJQvFW
— Heizenberger (@HeizenbergerOTC) March 4, 2019
Loaded low 40's this am, if she goes it's gonna fly
52s clearing here .. looks thin
Held at DTC means they're trading.........
Unless you know something about '33% insider ownership'.
70 something held at DTC.. makes it 30M float
What are you basing that on? I show 108 OS with only 16 Restricted ...that makes the Float 92 .......
z
You should redo that $APVS IBox buddy.........
z
33% insider ownership here too on a 30 milly float
Wow what did i miss here?
What’s up here merger or custodian play?
$APVS volume usually means something in OTC, not sure what it is yet but there is potential for acquisitions? Still looking into more DD but i am very interested in what is going on and im happy i bought the cheap shares today with Friday beer sellers giving them away pic.twitter.com/k9cwM3ZWY2
— Heizenberger (@HeizenbergerOTC) March 1, 2019
$APVS Article comparing APVS and $SCSC which deals with the same line of business. SCSC is a 38 dollar stock... APVS has 33% insider ownership though and is usually a good sign they expect their stock to rise in future..https://t.co/ZSOQUGrsZX pic.twitter.com/PLMqgZI6yF
— Heizenberger (@HeizenbergerOTC) March 1, 2019
$APVS This stock has a history of making some serious runs. Last run went to .06 cents and with a 30 M float that can happen in a blink of an eye. The loading was clear today as buys were coming in big batches. Thinking a big run Monday, looking to buy more at open.. pic.twitter.com/9cc6YayYY3
— Heizenberger (@HeizenbergerOTC) March 1, 2019
$APVS: Breaking out now... hitting $0.0049
Something in the works on this ticker.
Sudden volume over 2days.. more today.
Follow the Money.
GO $APVS
~ $APVS ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$APVS has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "APVS" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "APVS": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=APVS ~
Search Ihub for "APVS" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=APVS ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Net revenues 0.00
Did not happen ...
APVS Security Details
Share Structure
Market Value1 $14,143,726 a/o Jun 07, 2013
Shares Outstanding 101,026,612 a/o May 15, 2013
Float Not Available
Authorized Shares 200,000,000 a/o Sep 21, 2010
Par Value 0.001
Shareholders
Shareholders of Record 271 a/o May 13, 2013
Corporate Actions Ex. Date Record Date Pay Date
Security Notes
•Capital Change=shs increased by 2 for 1 split. Ex-date=04/03/2000. Rec date=03/15/2000. Pay date=04/01/2000.
•Capital Change=shs decreased by 1 for 5 split. Pay date=07/05/2002.
Short Selling Data
Short Interest 0 (-100%)
Feb 28, 2013
Significant Failures to Deliver No
Transfer Agent(s)
Signature Stock Transfer, Inc.
These guys have been licked, washed up for years. I am surprised they are still around. Reverse split coming soon. Watch out!
APVS - Email To Investors
Applied Visual Sciences India Business Development OutcomesTuesday, January 3, 2012 2:38 PM
From: "Press Release" <pressrelease@guardiantechintl.com>
Posted on January 3, 2012 by APVS
During the two week period ended December 17th, executives from Signature Mapping Medical Sciences traveled to India as part of an overall strategy to establish TBDx in India. The strategic objectives for the trip included the following:
Demonstrate the TBDx fully automated hardware-software technology platform to as many TB stakeholders as possible. This is a key objective for penetrating any new market. Interacting with the technology creates the ‘wow factor’ that cannot be achieved by simply discussing its capabilities.
Affect healthcare policy, with respect to TB diagnostics, by meeting with and educating key ministers in healthcare and technology.
Establish key business relationships with private Indian companies to accomplish important goals and needs:
Marketing & sales support.
Installation, training and maintenance support.
Joint project proposal efforts aimed at securing R&D project funding.
Joint venture with an Indian company to deliver TB diagnostics via mobile vans.
Meetings with key government healthcare officials to develop governmental funding for R&D projects.
Meeting with the Wellcome Trust Director of Operations in India to discuss our grant proposal, timing, and expectations.
We successfully accomplished each of the above objectives and, in addition, established valuable new contacts, advocates and opportunities. Interest was so high and created a significant amount of post-trip follow-up activities, including a return to India during the latter part of January or early February.
We accomplished approximately twenty group demonstrations of TBDx to approximately fifty individuals. Included in the demonstrations:
Top government healthcare officials from both the Central and State levels,
Apollo Hospitals Group www.apollohospitals.com,
All India Institute of Medical Sciences www.aiims.edu,
The International Union Against Tuberculosis and Lung Disease www.theunion.org,
Carl Zeiss Microscopes www.zeiss.com,
Foundation for Innovative New Diagnostics www.finddiagnostics.org,
The Bill and Melinda Gates Foundation www.gatesfoundation.org,
Department of Biotechnology www.dbtindia.nic.in,
LRS Institute of Tuberculosis & Respiratory Diseases www.lrsitbrd.nic.in ,
World Health Partners worldhealthpartners.org,
Gennova Biopharmaceuticals Ltd. www.emcure.co.in,
Prosix Softron PVT. LTD www.prosixsoftron.in,
DSS Image Tech www.dssimage.com,
Oncquest www.oncquest.net.
The overall reaction to the demonstrations was overwhelmingly positive with comments ranging from: “wow” to “why do you need auto-detect when the images are so sharp and clear” to “how do I get this technology now!” Since most, if not all of the institutions, were unaware of our technology and now have a strong desire to deploy TBDx within their laboratories, ramping up their budgets to support hardware procurement will be a key activity. As we move forward it will be important to develop finance/leasing options to spread the costs over a longer period of time.
Most discussions about the technology centered on a couple of key areas.
First and foremost was the impact that TBDx could have on reducing the number of false negatives (missed positive cases of TB). Using auto-detect algorithms like those used for Auramine would very obviously impact this problem. However, most groups were interested in what we thought the reduction would look like using only the visualization technology for Ziehl-Neelsen (ZN). Since we had no supporting clinical data to address the question, most groups assumed that it would have a significant impact, but would need to be determined by a clinical trial.
The second most common question was the ability of the technology to detect extra-pulmonary TB. Again our response was that we believe it to be possible, but that we have not undertaken a project to develop the algorithms.
Lastly, it was suggested that we submit a grant proposal to do research and development on the detection of the bacilli using ‘vital stains’. Vital stains would eliminate the need for ZN processing thereby reducing the cost and time to diagnose.
Our goal was to develop a buzz about the technology and we definitely accomplished it. Most of the scientists did not believe that automated image capture of stained TB slides could ever be accomplished due to inherent image acquisition challenges, the vast variations in slide staining quality and without using oil immersion. Seeing TBDx was definitely believing!
From our efforts we have been invited to participate in several large clinical trials with implications for an endorsement from the World Health Organization. In addition, we have multiple organizations interested in submitting joint R&D grant proposals to various funding agencies. We have also commenced the negotiations with several private organizations to provide sales, marketing, support and joint venture business opportunities. Listed below are highlights of a few of the meetings we held.
Our meeting with the International Union Against Tuberculosis and Lung Disease (IUATLD) went very well. The ‘Union” was impressed with the clarity of the ZN images and was very interested in assisting the company further evaluate the technology in India. Conference calls have been scheduled in early January to discuss the role IUATLD could play in introducing our technology into the Indian market.
During our presentation to the Foundation for Innovative New Diagnostics (FIND) a question arose about our ability to interface with microscopes manufactured by Carl Zeiss Microscopes. Since we have been unable to gain a working arrangement with Zeiss’s headquarters, the FIND representative urged key local Zeiss representatives to experience the technology. The Zeiss representatives immediately grasp the technology and its importance to TB diagnostics in India and beyond, and will be discussing the technology with headquarter officials in Geneva. All parties agreed that we should develop a solution using the WHO-endorsed Zeiss iLED Primo Star Microscope. Currently we are making arrangements to have a unit shipped to our office for evaluation and integration.
Although organizations such as the Bill & Melinda Gates Foundation (BMGF) see molecular diagnostics (Xpert) as the future in TB diagnostics, they acknowledged their mission to use any technology that will help fight the TB pandemic. Because sputum microscopy is well-established and a low-cost solution it will remain a vital diagnostic tool particularly in resource poor countries. BMGF was intrigued by the role that TBDx could play in larger, more centralized labs where sputa is delivered for processing and the analysis and reporting is fully automated. Clinical trials to test the efficacy of a centralized delivery model (India is currently very highly fragmented in its laboratory landscape), using our technology for high volume processing of ZN stained specimens, is currently under discussions and will be a main topic upon our return to India.
In conclusion, we conducted a meeting and demonstration with the Wellcome Trust. Of primary interest to us was the status of our grant funding proposal. The Wellcome Trust explained our funding proposal had not been processed giving an explanation that it was due to an untimely filing (fact – it was an error on their end, not ours).
There was very encouraging news however, after viewing the TBDx system and its processing capabilities, The Wellcome Trust strongly encouraged us to resubmit our proposal. We discussed potential modifications to our original application which were heartily endorsed. We were personally ensured that our application would be processed in June 2012. While this is not the outcome we wanted, a relationship with The Wellcome Trust is extremely valuable to our efforts in India and beyond. We intend to submit our proposal by the 28th of January.
<< This electronic message transmission contains information from Guardian Technologies that may be proprietary, confidential and/or privileged. The information is intended only for the use of the individual(s) or entity named above. If you are not the intended recipient, be aware that any disclosure, copying or distribution or use of the contents of this information is strictly prohibited. If you have received this electronic transmission in error, please notify the sender by replying to the address listed in the "From:" field. >>
Me thinks time to move on, taking my very bruised apples and going home.
APVS Video Chart 7/7/11
http://www.videocharts.qualitystocks.net
Applied Visual Sciences, Inc. is not a current client of QualityStocks
retail buying going on and MM's are ready to start the trend..http://stockcharts.com/h-sc/ui?s=APVS&p=D&b=5&g=0&id=p18830060668
this is what we look for is a safe low float charty play with all indicators in order, here you can see the cmf stockRSI ADX and the 5 10 and 20 day divergence.....beauty...http://stockcharts.com/h-sc/ui?s=APVS&p=D&b=5&g=0&id=p14250544209
•Formerly=Guardian Technologies International, Inc. until 7-2010
impressive restructuring going on with this
HERNDON, VA, Oct 19, 2010 (MARKETWIRE via COMTEX) -- Applied Visual Sciences (APVS) announced today that, on October 15, 2010, it entered into an agreement with the holders of the company's outstanding Series A 10% Senior Convertible Debentures due November 7, 2008, that extends the maturity date of the debentures, provides that the debentures will be non-interest bearing through the date of maturity, and for certain other amendments to the terms of the debentures and related agreements.
Under the terms of the agreement, the convertible debenture holders have agreed to extend the maturity of the notes to June 30, 2011. The debenture holders agreed to waive payment of approximately $638,163 of accrued but unpaid interest, late fees, mandatory default penalties totaling $2,496,149 and other amounts due under the debentures, in consideration of which the company agreed to issue an aggregate of 2,552,653 shares. Also, the debenture holders have agreed to waive prior breaches and defaults under the debentures and related debenture transaction documents and to release the company from related claims. The remaining principal amount of the amended debentures is $1,688,205 and will be non-interest bearing through the maturity date. Subject to the company's stock satisfying certain price and volume requirements, the holders have agreed to a provision permitting the company to force a conversion of the debentures. The holders have also agreed that the company is no longer required to register under the Securities Act the resale of the shares underlying their debentures and related warrants. Currently, the debentures are convertible at a price of $0.25. The agreement contains certain other amendments, representations and warranties of the parties and conditions to closing.
In addition, the company has been advised that, in March 2010, a strategic investor in the company, Dr. Joshua P. Prager, purchased approximately $838,205 in principal amount of the outstanding convertible debentures and certain related stock warrants from three of the original institutional investors in the company's 2006 debenture offering.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
312
|
Created
|
12/08/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |